Continuous glucose monitoring is continuing to expand beyond its traditional role in diabetes care.
On Wednesday, Silicon Valley-based startup Signos raised $20 million for its glucose monitoring platform for weight loss and management. Dexcom, Blue Cross Blue Shield of Alabama and GV (Google Ventures) participated in the investment round, which brought Signos’ fundraising total to $57 million since its founding in 2018.
The company combines continuous glucose monitoring technology with an app and coaching program designed to help users better understand how diet and lifestyle choices affect their metabolism.
Signos relies on Dexcom’s Stelo sensor, which became the first over-the-counter continuous glucose monitor cleared by the FDA in 2024. Signos’ app analyzes the glucose data collected by the device and provides personalized recommendations to help users make dietary and lifestyle changes.
Investors see the startup’s platform as complementary to the growing use of GLP-1 drugs, which have fueled unprecedented consumer interest in weight loss and management.
GLP-1s can be helpful tools for many people, but they don’t teach long-term metabolic understanding, pointed out Signos CEO Sharam Fouladgar-Mercer. Signos aims to drive behavior change by pairing glucose data with AI-generated insights that help users understand how their bodies respond to food.
“Many people regain weight after stopping GLP-1s because they return to the same patterns without realizing it. Without understanding how food, meal timing, movement and stress affect their body, people often struggle to maintain results once appetite suppression fades,” Fouladgar-Mercer explained.
He sees glucose as a key indicator of how the body processes and uses energy. Most people never pay attention to their glucose levels unless they’re diabetic — yet it affects energy, cravings, fat storage, mood and long-term metabolic health, Fouladgar-Mercer noted.
More than 115 million adults have prediabetes in the U.S., and more than 80% of them are unaware of the condition, he added.
“The rise of CGMs for those without diabetes creates access to knowledge. However, access without interpretation is overwhelming,” Fouladgar-Mercer remarked.
Signos’ technology is designed to make that data more understandable and actionable. It’s the only FDA-cleared CGM system for weight management, which Fouladgar-Mercer said allows the company to operate its system as a medical device and integrate CGM data into a single user-facing platform.
Signos subscriptions cost between $129 and $449 per month, depending on the length of the user’s commitment.
Fouladgar-Mercer noted that the market is transitioning from primarily cash-pay toward more employer-sponsored coverage — especially among self-insured employers focused on obesity and GLP-1 cost management.
But widespread reimbursement from traditional health plans is still early, so employer benefits are the primary growth channel Signos is targeting as it deploys its new round of capital.
Photo: Tatiana Meteleva, Getty Images
